SMT-738: a novel small-molecule inhibitor of bacterial lipoprotein transport targeting Enterobacteriaceae.

"E. Breidenstein, N. Khan, T. Duffy, C. Coward, T. Avis, O. Abdulle, and C. Mason were full-time employees of Summit Therapeutics and may have stock options and shares. C. Li is a full-time employee of Summit Therapeutics and may have stock options and shares."

"Research reported in this publication is supported by CARB-X. CARB-X’s funding for this project is provided in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number: 75A50122C00028, and by awards from Wellcome (WT224842) and Germany’s Federal Ministry of Education and Research (BMBF). The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders."